134 related articles for article (PubMed ID: 30728107)
1. Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
Martín-Escolano R; Marín C; Vega M; Martin-Montes Á; Medina-Carmona E; López C; Rotger C; Costa A; Sánchez-Moreno M
Bioorg Med Chem; 2019 Mar; 27(5):865-879. PubMed ID: 30728107
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
Olmo F; Rotger C; Ramírez-Macías I; Martínez L; Marín C; Carreras L; Urbanová K; Vega M; Chaves-Lemaur G; Sampedro A; Rosales MJ; Sánchez-Moreno M; Costa A
J Med Chem; 2014 Feb; 57(3):987-99. PubMed ID: 24410674
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological in vitro and in vivo Evaluation of 2-(5-Nitroindazol-1-yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease.
Martín-Escolano R; Aguilera-Venegas B; Marín C; Martín-Montes Á; Martín-Escolano J; Medina-Carmona E; Arán VJ; Sánchez-Moreno M
ChemMedChem; 2018 Oct; 13(19):2104-2118. PubMed ID: 30098232
[TBL] [Abstract][Full Text] [Related]
4. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo identification of tetradentated polyamine complexes as highly efficient metallodrugs against Trypanosoma cruzi.
Olmo F; Cussó O; Marín C; Rosales MJ; Urbanová K; Krauth-Siegel RL; Costas M; Ribas X; Sánchez-Moreno M
Exp Parasitol; 2016 May; 164():20-30. PubMed ID: 26874306
[TBL] [Abstract][Full Text] [Related]
6. Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
Olmo F; Guardia JJ; Marin C; Messouri I; Rosales MJ; Urbanová K; Chayboun I; Chahboun R; Alvarez-Manzaneda EJ; Sánchez-Moreno M
Eur J Med Chem; 2015 Jan; 89():683-90. PubMed ID: 25462275
[TBL] [Abstract][Full Text] [Related]
7. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
8. Tetradentate polyamines as efficient metallodrugs for Chagas disease treatment in murine model.
Olmo F; Costas M; Marín C; Rosales MJ; Martín-Escolano R; Cussó O; Gutierrez-Sánchez R; Ribas X; Sánchez-Moreno M
J Chemother; 2017 Apr; 29(2):83-93. PubMed ID: 27251893
[TBL] [Abstract][Full Text] [Related]
9. Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
Paucar R; Martín-Escolano R; Moreno-Viguri E; Azqueta A; Cirauqui N; Marín C; Sánchez-Moreno M; Pérez-Silanes S
Bioorg Med Chem; 2019 Sep; 27(17):3902-3917. PubMed ID: 31345745
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
[TBL] [Abstract][Full Text] [Related]
12. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
Moreno-Viguri E; Jiménez-Montes C; Martín-Escolano R; Santivañez-Veliz M; Martin-Montes A; Azqueta A; Jimenez-Lopez M; Zamora Ledesma S; Cirauqui N; López de Ceráin A; Marín C; Sánchez-Moreno M; Pérez-Silanes S
J Med Chem; 2016 Dec; 59(24):10929-10945. PubMed ID: 28002965
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
Sánchez-Moreno M; Marín C; Navarro P; Lamarque L; García-España E; Miranda C; Huertas O; Olmo F; Gómez-Contreras F; Pitarch J; Arrebola F
J Med Chem; 2012 May; 55(9):4231-43. PubMed ID: 22443115
[TBL] [Abstract][Full Text] [Related]
15. Effects of astaxanthin in mice acutely infected with Trypanosoma cruzi.
Contreras-Ortiz JME; Barbabosa-Pliego A; Oros-Pantoja R; Aparicio-Burgos JE; Zepeda-Escobar JA; Hassan-Moustafa WH; Ochoa-García L; Uxúa Alonso-Fresan M; Tenorio Borroto E; Vázquez-Chagoyán JC
Parasite; 2017; 24():17. PubMed ID: 28560955
[TBL] [Abstract][Full Text] [Related]
16. Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
Muscia GC; Roldán Pacheco FJ; Asís SE; Buldain GY; Frank FM
Eur J Med Chem; 2020 Jan; 186():111877. PubMed ID: 31771829
[TBL] [Abstract][Full Text] [Related]
17. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo experimental models for drug screening and development for Chagas disease.
Romanha AJ; Castro SL; Soeiro Mde N; Lannes-Vieira J; Ribeiro I; Talvani A; Bourdin B; Blum B; Olivieri B; Zani C; Spadafora C; Chiari E; Chatelain E; Chaves G; Calzada JE; Bustamante JM; Freitas-Junior LH; Romero LI; Bahia MT; Lotrowska M; Soares M; Andrade SG; Armstrong T; Degrave W; Andrade Zde A
Mem Inst Oswaldo Cruz; 2010 Mar; 105(2):233-8. PubMed ID: 20428688
[TBL] [Abstract][Full Text] [Related]
19. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
20. Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
Martín-Escolano R; Moreno-Viguri E; Santivañez-Veliz M; Martin-Montes A; Medina-Carmona E; Paucar R; Marín C; Azqueta A; Cirauqui N; Pey AL; Pérez-Silanes S; Sánchez-Moreno M
J Med Chem; 2018 Jul; 61(13):5643-5663. PubMed ID: 29883536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
